×
About 184,390 results

I Am CDC - Sharon McAleer
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/415940

I've been at CDC since May of 2000. I always felt my path to CDC was accidental, but over the years, I've come to realize, it's perfect for me. I grew up in Ireland and was a bit of a sports nut.... big into Gaelic football, running, cycling, and swimming-I still love that stuff! When I was a student at Queens University in Belfast, I never imagined that I would end up working for one of th...

Continuous-Release Anti-VEGF Device for AMD Wins FDA Approval
https://www.medpagetoday.com/ophthalmology/generalophthalmology/95225

Oct 23rd, 2021 - The FDA has approved a first-of-its kind continuous delivery system for anti-VEGF therapy for neovascular (wet) age-related macular degeneration (AMD). The Susvimo ocular implant continuously releases 100 mg/mL of ranibizumab directly to the retina over 6 months. Initial implantation and refill can be performed during an office visit with an ophthalmologist. In contrast, conventional intravitre...

Motor imagery improves MS
https://www.mdedge.com/neurology/article/247794/multiple-sclerosis/motor-imagery-improves-ms
Jim Kling

Oct 22nd, 2021 - Motor imagery (MI) is a useful tool in the management of multiple sclerosis (MS), with the potential to improve balance, walking, and even cognitive function and mental health. It’s a technique that many think of as the realm of professional athletes, who use it to help mentally prepare for physical activity.

TAS-102 Plus Bevacizumab Misses PFS End Point in Frontline Unresectable Metastatic CRC
https://www.onclive.com/view/tas-102-plus-bevacizumab-misses-pfs-end-point-in-frontline-unresectable-metastatic-crc

Oct 22nd, 2021 - The frontline combination of trifluridine/tipiracil (TAS-102; Lonsurf) and bevacizumab (Avastin) was not found to result in a significant improvement in progression-free survival (PFS) over capecitabine and bevacizumab in patients with unresectable metastatic colorectal cancer (mCRC) who are not eligible to receive intensive therapy, missing the primary end point of the phase 3 SOLSTICE trial (...

NSCLC Incidence Declining, Except in Stage I Disease
https://www.medpagetoday.com/radiology/diagnosticradiology/95219

Oct 22nd, 2021 - The overall incidence of non-small cell lung cancer (NSCLC) decreased from 2010 to 2017, with the incidence of stage IV disease falling, and stage I disease rising, researchers determined. A cross-sectional epidemiological analysis showed that NSCLC incidence per 100,000 population declined from 46.4 to 40.9 during the study period. While the incidence of stage II, IIIA, and IIIB disease was st...

A Wealth of Therapeutic Advances in Lung Cancer Stress a Need for Early NGS Testing
https://www.onclive.com/view/a-wealth-of-therapeutic-advances-in-lung-cancer-stress-a-need-for-early-ngs-testing

Oct 22nd, 2021 - The overwhelming number of options for the treatment of patients with lung cancer underscores the importance of broad molecular testing up front to ensure patients receive optimal care, said Stephen V. Liu, MD. Our strategies [for managing lung cancer] are becoming more sophisticated and precise, but the first step of broad next-generation sequencing [NGS] is really the key. NGS is essential t...

Too Many TAVR Centers Are Clustered Around Well-to-Do Communities
https://www.medpagetoday.com/cardiology/pci/95213

Oct 22nd, 2021 - The proliferation of transcatheter aortic valve replacement (TAVR) programs in the U.S. was largely limited to metropolitan areas and hospitals serving relatively affluent patients, a study found. Only 2% of the 583 hospitals with a TAVR program by the end of 2018 were not located in metropolitan areas, and there was only one rural center. Furthermore, half of new programs established in 2012 t...

CANADA STOCKS-TSX flat as weakness in tech, healthcare offset commodity-linked gains
https://www.reuters.com/article/canada-stocks/canada-stocks-tsx-flat-as-weakness-in-tech-healthcare-offset-commodity-linked-gains-idUSL4N2RI3BH

Oct 22nd, 2021 - (Updates prices, adds analyst comment) Oct 22 (Reuters) - Canada’s main stock index was little changed on Friday, as weakness in technology and healthcare stocks offset commodity-linked gains, however the benchmark index was on course for its third straight week of gains. At 9:42 a.m. ET (13:42 GMT), the Toronto Stock Exchange’s S&P/TSX composite index was down 5.76 points, or 0.03%, at 21,206....

Institutional Perspectives in Cancer Webinar- Lung: Chaired by Edward B. Garon, MD
https://www.onclive.com/view/institutional-perspectives-in-cancer-webinar--lung-chaired-by-edward-b-garon-md

Oct 21st, 2021 - Institutional Perspectives in Cancer- Lung: Chaired by Edward B. Garon, MD The live filming of this virtual event in our IPC series is now on-demand. OncLive is proud to present the State of the Science Summits and a new virtual event, Institutional Perspectives in Cancer (IPC). Each summit and webinar will convene for a short meeting designed to educate healthcare professionals on the clin...

Institutional Perspectives in Cancer- Lung: Chaired by Stephen Liu, MD
https://www.onclive.com/view/institutional-perspectives-in-cancer--lung-chaired-by-stephen-liu-md

Oct 21st, 2021 - Institutional Perspectives in Cancer- Lung: Chaired by Stephen Liu, MD The live filming of this virtual event in our IPC series is now on-demand. OncLive is proud to present the State of the Science Summits and a new virtual event, Institutional Perspectives in Cancer (IPC). Each summit and webinar will convene for a short meeting designed to educate healthcare professionals on the clinical...

OncLive State of Science Summit: Lung Cancer: Co-Chaired by Luis E. Raez, MD, FACP, FCCP and Edgardo S. Santos Castillero, MD, FACP
https://www.onclive.com/view/onclive-state-of-science-summit-lung-cancer-co-chaired-by-luis-e-raez-md-facp-fccp-and-edgardo-s-santos-castillero-md-facp

Oct 21st, 2021 - OncLive State of Science Summit: Lung Cancer: Co-Chaired by Luis E. Raez, MD, FACP, FCCP and Edgardo S. Santos Castillero, MD, FACP Speakers Luis E. Raez, MD, FACP, FCCP | Memorial Cancer Institute/ Memorial Health Care System Edgardo S. Santos Castillero, MD, FACP | Florida Precision Oncology/GenesisCare Janakiraman Subramanian, MD | Saint Luke’s Cancer Specialists Alberto Chiappori, MD...

Institutional Perspectives in Cancer- Breast: Chaired by Paul L. Baron, MD
https://www.onclive.com/view/institutional-perspectives-in-cancer--breast-chaired-by-paul-l-baron-md

Oct 21st, 2021 - The live filming of this virtual event in our IPC series is now on-demand. OncLive is proud to present the State of the Science Summits and a new virtual event, Institutional Perspectives in Cancer (IPC). Each summit and webinar will convene for a short meeting designed to educate healthcare professionals on the clinical benefits associated with new science driving new thinking in cancer manag...

Dr. Brayer on the Emergence of BiTEs and Bispecific Antibodies in Multiple Myeloma
https://www.onclive.com/view/dr-brayer-on-the-emergence-of-bites-and-bispecific-antibodies-in-multiple-myeloma

Oct 21st, 2021 - Jason Brayer, MD, PhD, assistant member, malignant hematology program at Moffitt Cancer Center, discusses the emergence of bispecific T-cell engagers (BiTEs) and bispecific antibodies in multiple myeloma. T-cell redirecting therapies, such as BiTEs and bispecific antibodies, are emerging in multiple myeloma, which could expand the cellular paradigm beyond CAR T-cell therapy, Brayer explains....

TG-1701 Induces Strong Response Rates, Fewer AEs in Relapsed/Refractory CLL
https://www.onclive.com/view/tg-1701-induces-strong-response-rates-fewer-aes-in-relapsed-refractory-cl

Oct 21st, 2021 - TG-1701 administered as monotherapy or in combination with ublituximab (TGTX-1101) and umbralisib (Ukoniq) demonstrated promising overall response rates (ORR) and with relatively few adverse events (AEs) in patients with chronic lymphocytic leukemia (CLL), according to lead author Chan Cheah, MBBS. He added that the agent is a more specific targeting BTK inhibitor which reduces off-target toxic...

Experts Answer Audience Questions Related to Adverse Events of BTKi
https://www.onclive.com/view/experts-answer-audience-questions-related-to-adverse-events-of-btki

Oct 21st, 2021 - Carrie Lenneman, MD, MSCI: In light of time, I’ll move to a couple of questions if you’re ready for that. Farrukh Awan, MD: Yes. Carrie Lenneman, MD, MSCI: The first one is, Have you seen low heart rate or bradycardia with ibrutinib? I can honestly say no, I have not seen that be a problem that wasn’t preidentified early. I don’t know what your experience is. Farrukh Awan, MD: I hav...

Patients seeking infertility care report infrequent counseling on weight loss
https://www.mdedge.com/obgyn/article/247716/reproductive-endocrinology/patients-seeking-infertility-care-report-infrequent
Jennifer Lubell

Oct 21st, 2021 - Physicians could be doing a better job of counseling patients with obesity and overweight on weight loss and fertility. A study of 48 women seeking infertility care at a large academic center found that less than half received advice on weight loss from their primary ob.

Lessons Learned May Hold the Key for Improving Outcomes in Fibrolamellar Carcinoma
https://www.onclive.com/view/lessons-learned-may-hold-the-key-for-improving-outcomes-in-fibrolamellar-carcinoma

Oct 21st, 2021 - Fibrolamellar carcinoma is an extremely rare form of liver cancer that affects approximately 1 in 5 million Americans.1 However, because the disease appears so infrequently, it may be underdiagnosed, said Mark Yarchoan, MD. He added that, with an annual age-adjusted incidence rate of just 0.02 per 100,000 in the United States, fibrolamellar carcinoma is so uncommon that investigators have yet t...

Yellow pruritic eruption
https://www.mdedge.com/familymedicine/article/247705/dermatology/yellow-pruritic-eruption
MDedge Family Medicine;

Oct 21st, 2021 - This pruritic, eruption with yellowing atrophy and telangiectasias on the lower extremities is a classic presentation for necrobiosis lipoidica (NL). NL is a chronic granulomatous disorder with a predilection for the lower extremities.

Dr. Lee on the Current State of Molecular Testing in Early-Stage NSCLC
https://www.onclive.com/view/dr-lee-on-the-current-state-of-molecular-testing-in-early-stage-nsclc

Oct 20th, 2021 - Jay Moon Lee, MD, chief, Division of Thoracic Surgery, associate professor of surgery, surgical director, University of California, Los Angeles (UCLA) Thoracic Oncology Program, surgical director, UCLA Center for Esophageal Disorders, member, UCLA Sarcoma Program, Jonsson Comprehensive Cancer Center, UCLA Health, discusses the current state of molecular testing in early-stage non–small cell lun...

Cal/BD foam gains ground among patients with plaque psoriasis
https://www.mdedge.com/dermatology/article/247682/psoriasis/cal/bd-foam-gains-ground-among-patients-plaque-psoriasis

Oct 20th, 2021 - Key clinical point: Proactive management with calcipotriene 50 μg/g and betamethasone dipropionate 0. 5 mg/g (Cal/BD) foam vs.